Clinical utility of risk modelsto refer patients with adnexal masses to specialized oncology care: Multicenter external validation using decision curve analysis

Laure Wynants, Dirk Timmerman, Jan Y. Verbakel, Antonia Testa, Luca Savelli, Daniela Fischerova, Dorella Franchi, Caroline Van Holsbeke, Elisabeth Epstein, Wouter Froyman, Stefano Guerriero, Alberto Rossi, Robert Fruscio, Francesco P.G. Leone, Tom Bourne, Lil Valentin, Ben Van Calster

Research output: Contribution to journalArticlepeer-review

Abstract

Purpose: To evaluate the utility of preoperative diagnostic models for ovarian cancer based on ultrasound and/or biomarkers for referring patients to specialized oncology care. The investigated models were RMI, ROMA, and 3 models from the International Ovarian Tumor Analysis (IOTA) group [LR2, ADNEX, and the Simple Rules risk score (SRRisk)]. Experimental Design: A secondary analysis of prospectively collected data from 2 cross-sectional cohort studies was performed to externally validate diagnostic models. A total of 2, 763 patients (2, 403 in dataset 1 and 360 in dataset 2) from 18 centers (11 oncology centers and 7 nononcology hospitals) in 6 countries participated. Excised tissue was histologically classified as benign or malignant. The clinical utility of the preoperative diagnostic models was assessed with net benefit (NB) at a range of risk thresholds (5%-50% risk of malignancy) to refer patients to specialized oncology care. We visualized results with decision curves and generated bootstrap confidence intervals. Results: The prevalence of malignancy was 41% in dataset 1 and 40% in dataset 2. For thresholds up to 10% to 15%, RMI and ROMA had a lower NB than referring all patients. SRRisks and ADNEX demonstrated the highest NB. At a threshold of 20%, the NBs of ADNEX, SRrisks, and RMI were 0.348, 0.350, and 0.270, respectively. Results by menopausal status and type of center (oncology vs. nononcology) were similar. Conclusions: All tested IOTA methods, especially ADNEX and SRRisks, are clinically more useful than RMI and ROMA to select patients with adnexal masses for specialized oncology care.

Original languageEnglish
Pages (from-to)5082-5090
Number of pages9
JournalClinical Cancer Research
Volume23
Issue number17
DOIs
Publication statusPublished - Sep 1 2017

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Clinical utility of risk modelsto refer patients with adnexal masses to specialized oncology care: Multicenter external validation using decision curve analysis'. Together they form a unique fingerprint.

Cite this